Related Experiment Video
Updated: Jul 6, 2026
Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
Published on: March 13, 2018
Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment
Yan-Xia Mi1, Ya-Hong Long, Yun-Chun Li
1Department of Nuclear Medicine, West China Hospital, Sichuan University, 37 Guoxue Alley, Chengdu 610041, Sichuan Province, China.
Abstract:
For over one hundred years, viruses have been recognized as capable of killing tumor cells. At present, people are still researching and constructing more suitable oncolytic viruses for treating different malignant tumors. Although extensive studies have demonstrated that herpes simplex virus type 1 (HSV-1) is the most potential oncolytic virus, therapies based on herpes simplex virus type 1 vectors still arouse bio-safety and risk management issues. Researchers have therefore introduced the new idea of treating cancer with HSV-1 mutants labeled with radionuclides, combining radionuclide and oncolytic virus therapies. This overview briefly summarizes the status and mechanisms by which oncolytic viruses kill tumor cells, discusses the application of HSV-1 and HSV-1 derived vectors for tumor therapy, and demonstrates the feasibility and prospect of HSV-1 mutants labeled with radionuclides for treating tumors.
Insights
Researchers are exploring oncolytic viruses, like herpes simplex virus type 1 (HSV-1), for cancer treatment. Combining HSV-1 with radionuclides offers a promising, safer approach to tumor therapy.
Area of Science:
- Oncolytic virotherapy
- Cancer research
- Radiopharmaceutical therapy
Background:
- Viruses have been known to kill tumor cells for over a century.
- Herpes simplex virus type 1 (HSV-1) shows significant potential as an oncolytic virus.
- Current HSV-1 therapies face bio-safety and risk management challenges.
Purpose of the Study:
- To summarize the mechanisms of oncolytic viruses in killing tumor cells.
- To discuss the application of HSV-1 and its vectors in tumor therapy.
- To demonstrate the feasibility of using radionuclide-labeled HSV-1 mutants for cancer treatment.
Main Methods:
- Review of existing literature on oncolytic viruses and HSV-1.
- Analysis of mechanisms by which oncolytic viruses induce tumor cell death.
- Evaluation of safety and efficacy data for HSV-1 based therapies.
- Exploration of radionuclide labeling techniques for HSV-1 mutants.
Main Results:
- Oncolytic viruses effectively kill tumor cells through various mechanisms.
- HSV-1 and its derived vectors are potent candidates for cancer therapy.
- Radionuclide-labeled HSV-1 mutants present a novel strategy to overcome safety concerns.
- This combined approach merges the benefits of virotherapy and radionuclide therapy.
Conclusions:
- Oncolytic virotherapy, particularly using HSV-1, is a developing field in cancer treatment.
- Radionuclide-labeled HSV-1 mutants offer a potentially safer and more effective therapeutic strategy.
- Further research into HSV-1 mutants labeled with radionuclides is warranted for clinical application.
